louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05968781: Predictive Factors for Successful Videolaryngoscopic Intubation Without Stylet
Official title: A Prospective Observational Study of Predictive Factors for Successful Videolaryngoscopic Intubation Without Stylet
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Intubation; Difficult or Failed
Videolaryngoscopy
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2023-08-01
Enrollment: 226
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adult patients undergoing general anesthesia and endotracheal intubation

Brief summary: The investigators aimed to evaluate the predictive factors for successful videolaryngoscopic intubation without stylet.


Eligibility criteria: Inclusion Criteria:

* Patients aged 19 years and older
* Patients undergoing general anesthesia for elective surgery and requiring endotracheal intubation

Exclusion Criteria:

* Patients with suspected cervical spine injury
* Patients requiring rapid sequence induction and intubation.
* Patients with airway disorders
* Body Mass Index \> 35 kg/m2
* Patients with a history of difficult intubation or, based on clinical judgment, anticipated difficult intubation

Primary outcomes:
measure: First-pass success rate of videolaryngoscopic intubation without stylet
timeFrame: From the start of endotracheal intubation to 120 seconds
Secondary outcomes:
measure: Success rate of videolaryngoscopic intubation without stylet using BURP maneuver after failure of the first attempt
timeFrame: From the start of endotracheal intubation to 120 seconds
measure: Incidence of using a stylet for the success of videolaryngoscopic intubation after the failure of the second attempt using the BURP maneuver
timeFrame: From the start of endotracheal intubation to 120 seconds
measure: Incidence of successful endotracheal intubation after the failure of the third attempt using stylet
timeFrame: From the start of endotracheal intubation to 120 seconds
measure: Time to completion of endotracheal intubation
timeFrame: From the start of endotracheal intubation to 120 seconds
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
References:
Clinical trial NCT02918981: Nutritional Strategies to Augment the Postprandial Muscle Protein Synthetic Response to the Ingestion of a Low Dose of Protein in Middle-aged Women
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Aging
Lead sponsor: University of Illinois at Urbana-Champaign
Sponsor class: OTHER
First posted: 2016-09-29
Enrollment: 50
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Using stable isotope methodology, investigators will determine the postabsorptive and postprandial muscle protein synthetic response in 60 female adults (Age 50-79, BMI: \<30 kg/m2) immediately after an acute bout of resistance exercise. Participants will be divided in to 5 groups of twelve women (n=12). Each group will receive a different protein beverage or placebo to consume following the resistance exercise training. Group 1 will consume a beverage consisting of whey protein; group 2 will consume whey protein supplemented with additional leucine; group 3 will consume whey protein supplemented with additional leucine and hydrolyzed whey peptides; group 4 will consume whey protein supplemented with additional leucine and citrulline; group 5 will just consume water. During the testing, blood and muscle samples will be collected.


Eligibility criteria: Inclusion Criteria:

* BMI \<30 kg/m2
* Healthy, sedentary
* Either 20-30 years old or 50-79 years old

Exclusion Criteria:

* Tobacco use
* Allergies to milk consumption
* Unusually high protein consumption
* Vegan diet
* Allergies to antibiotics or xylocaine
* Phenylketonuria (PKU)
* Diagnosed GI tract diseases
* Arthritic conditions
* A history of neuromuscular problems
* Heart disease
* Metabolic disorders
* -Liver, kidney, or urinary disease
* Musculoskeletal problems
* Autoimmune disease
* Neurological disease
* Previous participation in amino acid tracer studies
* Predisposition to hypertrophic scarring or keloid formation
* Individuals on any medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or prescription strength acne medications).
* Individuals using thyroid medications or other medications affecting endocrine function
* Pregnancy
* Contraindications for exercise
* BMI ≥30
* supplements that influence protein metabolism (e.g omega 3 fish oils)

Primary outcomes:
measure: The myofibrillar protein synthetic response to protein ingestion
timeFrame: Postabsorptive for 3 hours, Postprandial for 4 hours hours
Secondary outcomes:
measure: mTORC1 phosphorylation
timeFrame: Baseline and at 2 and 4 hours after protein ingestion
Other outcomes:
Locations:
city: Urbana
country: United States
facility: Freer Hall
state: Illinois
Study officials:
affiliation: University of Illinois at Chicago
name: Nicholas A Burd, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00409110: Ocular Pulse Amplitude And Choroidal Laser Doppler Flowmetry
Official title: Relationship Between Ocular Pulse Amplitude And Choroidal Laser Doppler Flowmetry In Healthy Subjects
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Healthy
Keywords: Ocular Pulse Amplitude
Dynamic Contour Tonometry
Pulsatility Index
Choroidal Laser Doppler Flowmetry
Finometer
Lead sponsor: University Hospital, Basel, Switzerland
Sponsor class: OTHER
First posted: 2006-12-08
Enrollment: 10
Sex: ALL
Minimum age (years): 45
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: healthy subjects

Brief summary: This study intends to investigate the relationship between choroidal blood flow and ocular pulse amplitude (OPA).

Detailed description: One eye is randomly selected in 18 healthy subjects. OPA is assessed with Dynamic Contour Tonometry. Submacular choroidal blood flow is measured with Laser Doppler Flowmetry. During both examinations the systemic blood pressure is continuously recorded with Finometer. An average systolic and diastolic LDF parameter flow during 30 seconds are determined and the pulsatility index is calculated according to the formula (LDFsys-LDFdia)/LDFdia. An association of OPA with the LDF pulsatility index, systemic blood pressure values and mean intraocular pressure will be analysed.

Eligibility criteria: Inclusion Criteria:

* Healthy subjects should present no history of ocular diseases, of current topical medication, or of drug or alcohol abuse. Furthermore, a best corrected visual acuity above 20/25 in both eyes, lack of pathological findings upon a slit-lamp examination and dilated direct fundoscopy, and an IOP \< 21 mmHg in both eyes will be required.

Exclusion Criteria:

* History of chronic or recurrent severe inflammatory eye disease such as scleritis or uveitis.
* History of ocular trauma or intraocular surgery. History of infection or inflammation within the past 3 months.
* History and clinical evidence for other retinal disease such as age-related degeneration, or diabetic retinopathy.

Primary outcomes:
measure: An association of OPA with the LDF pulsatility index
timeFrame: 30 seconds
Secondary outcomes:
measure: An association of OPA with the systemic blood pressure values
timeFrame: 30 seconds
measure: An association of OPA with mean intraocular pressure
timeFrame: 30 seconds
Other outcomes:
Locations:
city: Basel
country: Switzerland
facility: University Eye Clinic Basel
state: Basel-Stadt
Study officials:
affiliation: University Eye Clinic Basel
name: Selim Orguel, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01761110: Pilot Test of a Community-based Buprenorphine Treatment Intervention
Official title: Development of a Community-based Buprenorphine Treatment Intervention
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Opioid Dependence
Injection Drug Use
Keywords: Opioid dependence
Injection drug use
Buprenorphine
Opioid agonist treatment
Access to care
HIV risk behaviors
Opioids
Lead sponsor: Albert Einstein College of Medicine
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
name: City University of New York
name: Washington Heights Corner Project
First posted: 2013-01-04
Enrollment: 77
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main goal of this study is to pilot test the community-based buprenorphine treatment (CBBT) intervention, examining buprenorphine treatment initiation, opioid use, and HIV risk behaviors. Two groups of participants will be followed for 60 days, with 3 research visits. One group will be enrolled prior to the CBBT intervention (pre-intervention), and one group after the CBBT intervention (post-intervention). Data sources will include questionnaires, urine toxicology tests, and medical record data. Investigators hypothesize that compared to the participants in the pre-intervention group, participants in the post-intervention group will be more likely to initiate buprenorphine treatment, reduce opioid use, and reduce high-risk HIV risk behaviors.


Eligibility criteria: Inclusion Criteria:

* at least 18 years old
* English or Spanish fluency
* ever injected drugs
* not receiving buprenorphine treatment (no prescribed buprenorphine in the previous 6 months)
* clients of our collaborating community-based organization
* interested in buprenorphine treatment

Exclusion Criteria:

* pregnant
* taking more than 60mg of methadone daily in the previous 30 days

Primary outcomes:
measure: initiation of buprenorphine treatment
timeFrame: 60 days
Secondary outcomes:
measure: opioid use
timeFrame: 60 days
Other outcomes:
measure: HIV risk behaviors
timeFrame: 60 days
Locations:
city: New York
country: United States
facility: Washington Heights Corner Project
state: New York
Study officials:
affiliation: Albert Einstein College of Medicine
name: Chinazo Cunningham, MD, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05922410: Different Maxillary Sinus 3D Shapes Assessment Using CBCT Volumetric Segmentation
Official title: Different Maxillary Sinus 3D Shapes Assessment Using CBCT Volumetric Segmentation: A Cross Sectional Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Cone-beam Computed Tomography
Maxillary Sinus
Anatomical Variations
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2023-06-28
Enrollment: 29
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: CBCT maxillofacial scans belonging to Egyptian individuals will be examined

Brief summary: the study aims to assist the different 3D shapes of maxillary sinus in adult individuals among Egyptian population,The data collection will be obtained from the data base available at the department of Oral and Maxillofacial Radiology, Faculty of Dentistry, Cairo University. CBCT images will be obtained from Egyptian patients who were referred to the CBCT unit in oral and maxillofacial radiology department for different purposes. The following radiographic examination will be done in Oral and Maxillofacial Radiology Department, Faculty Dentistry, Cairo University. semiautomated segmentation will be performed for the maxillary sinus in both side and then linear and 3D volume will be assessed for each sinus.


Eligibility criteria: Inclusion Criteria:

* CBCT scans of adult Egyptian patients, males and females, with age range between 18 and 50 years old. Patients will be divided into two age groups (group 1 less than or equal 30 years old, group2 more than 30 years old).
* CBCT scans of patient without previous orthodontic treatment.
* CBCT scans without any other treatment that might interfere with the natural course of maxillomandibular growth and development.

Exclusion Criteria:

-Scans with maxillary pathologies like (tumors, odontogenic lesions, bone lesions).

* Patients with traumatic injuries or fractures affecting the maxillary sinus.
* Patients with missing upper premolar or molar teeth in one side or both sides.
* Patients with skeletal asymmetries, craniofacial traumas and developmental anomalies such as palatal cleft.
* Images of low-resolution quality.
* Distortion of images or presence of any artifacts.

Primary outcomes:
measure: Assessment of different volumetric 3D shapes of maxillary sinus
timeFrame: 1 year
Secondary outcomes:
measure: Symmetrical assessment of maxillary sinus volumetric 3D shape in both sides in the same individual
timeFrame: 1 year
measure: Maxillary sinus volumetric 3D Shape with sex variables
timeFrame: 1 year
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00524810: Liposomal Doxorubicin and Docetaxel in Metastatic Breast Cancer
Official title: A Multi-center Phase II Study Evaluating the Efficacy and Tolerance of the Association of Liposomal Doxorubicin and Docetaxel in First Line Chemotherapy in Patients With Metastatic Breast Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Metastatic Breast Cancer
Lead sponsor: ARCAGY/ GINECO GROUP
Sponsor class: OTHER
First posted: 2007-09-05
Enrollment: 67
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Evaluation of safety and efficacy of a treatment associating Pegylated Liposomal Doxorubicin + Docetaxel in patients with metastatic breast cancer

Detailed description: Evaluation of safety and efficacy of a treatment associating Pegylated Liposomal Doxorubicin + Docetaxel in patients with metastatic breast cancer. Patients will receive pyridoxin to prevent cutaneo-mucinous toxicities.

Eligibility criteria: Inclusion Criteria:

* first metastatic chemo line
* presence of measurable or bone lesion
* at least one lesion outside the radiated areas
* can have previously received hormonotherapy, chemotherapy in adjuvant phase, radiotherapy if older than 4 weeks

Exclusion Criteria:

* only local tumoral progression
* symptomatic cerebral metastasis
* neuropathy \> NCI-CTC 2
* previous cancer within 10 years _ previous cancer within 10 years

Primary outcomes:
measure: Non-progression rate after 6 cycles
timeFrame: 6 months
Secondary outcomes:
measure: tolerance and toxicity
timeFrame: 6 months
measure: Tumor response and duration
timeFrame: 5 years
measure: Time to Progression
timeFrame: 5 years
measure: Overall survival
timeFrame: 5 years
Other outcomes:
Locations:
city: Paris
country: France
facility: Hôpital HOTEL DIEU
Study officials:
affiliation: Hôpital HOTEL DIEU - Paris
name: Laure CHAUVENET, MD, PHD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05905510: Lumbar Erector Spinae Plane Block and Fascia Iliaca Compartment Block After Total Hip Arthroplasty
Official title: Comparative Study Between Ultrasound-Guided Lumbar Erector Spinae Plane Block and Fascia Iliaca Compartment Block for Postoperative Analgesia After Total Hip Arthroplasty
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Analgesia
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2023-06-15
Enrollment: 75
Sex: ALL
Minimum age (years): 30
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Compare the analgesic efficacy of ultrasound-guided lumbar erector spinae plane block (L-ESPB) versus fascia iliaca compartment block (FICB) in patients scheduled for total hip arthroplasty.

Detailed description: Ultrasound-guided erector spinae plane (ESP) block is a recent regional anesthetic technique. It was first described by Forero et al. in 2016 for acute and chronic thoracic pain management. Local anesthetic (LA) is injected between the erector spinae muscle and the vertebra's transverse process, leading to the spread of LA cephalad, caudally, and through the paravertebral space.

Eligibility criteria: Inclusion Criteria:

1. Patients aged 30-75 years from both sexes.
2. ASA I-III scheduled for unilateral hip surgery under spinal anesthesia.

Exclusion Criteria:

1. Patients' refusal.
2. Patients who were unable to co-operate with researchers.
3. History of allergy to local anesthetics.
4. Local infection at the site of the block.
5. Patients with bleeding and coagulation disorders.
6. Patients with renal, hepatic, cardiac decompensation, or spine deformities.
7. Patients receiving opioids for chronic analgesic therapy
8. Body mass index \> 35 kg/m2

Primary outcomes:
measure: Assessment of postoperative pain
timeFrame: UP to 24 hour postoperatively
Secondary outcomes:
measure: Time required for the first rescue analgesia.
timeFrame: Up to 24 hours postoperatively
measure: The total postoperative rescue analgesic
timeFrame: first 24 hours postoperatively
measure: Adverse effects
timeFrame: Up to 24 hours postoperatively
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Tanta University Hospitals
state: Elgharbia
Study officials:
References:
Clinical trial NCT01229410: Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Vitrectomy
Lead sponsor: Allergan
Sponsor class: INDUSTRY
First posted: 2010-10-27
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: This study will evaluate the pharmacokinetics of brimonidine following a single intravitreal administration of the 200 ug or 400 ug Brimonidine Tartrate Posterior Segment Drug Delivery System in patients 2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy.


Eligibility criteria: Inclusion Criteria:

* Plan on having a pars plana vitrectomy for repair of a posterior segment condition (eg, epiretinal membrane, macular hole, vitreomacular traction)
* Visual acuity in the non-study eye better than 20/200

Exclusion Criteria:

* History of pars plana vitrectomy or retinal detachment surgery in the study eye
* Surgery or laser treatment in the study eye within 3 months
* Use of brimonidine, apraclonidine or other topical alpha-2-agonist in either eye within 2 weeks
* Intraocular infection or inflammation

Primary outcomes:
measure: Highest Vitreous Humor Level of Brimonidine in the Study Eye
timeFrame: 60 Days
Secondary outcomes:
measure: Highest Aqueous Humor Level of Brimonidine in the Study Eye
timeFrame: 60 Days
measure: Percentage of Patient Samples With Plasma Levels of Brimonidine Below the Limit of Quantitation (BLQ)
timeFrame: 60 Days
Other outcomes:
Locations:
city: Salt Lake City
country: United States
state: Utah
city: Prague
country: Czech Republic
Study officials:
affiliation: Allergan
name: Medical Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT01312610: Orange Juice Consumption and Cognitive Function
Official title: Effect of Chronic Orange Juice Consumption on Cognitive Function in Healthy Older Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Nerve Degeneration
Keywords: orange juice
cognitive function
flavonoids
flavanones
Lead sponsor: University of Reading
Sponsor class: OTHER
First posted: 2011-03-10
Enrollment: 40
Sex: ALL
Minimum age (years): 60
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: This study is investigating the effect of 8 weeks of orange juice supplementation on executive function in healthy older adults. The study is a controled, double-blind, crossover trial and involves a 8 week supplementation with a high flavonone orange juice and a carbohydrate-matched control. Volunteers consume 500ml of either the test juice or the control juice per day for an 8 week period. There is then an 8 week washout period before subjects proceed to the other arm of the study. Subjects are randomly assigned to either arm at the beginning of the study. Measures of cognitive function will be administered pre and post both test and control interventions. Blood pressure will also be measured and blood and urine samples will be collected to assess absorption of from the juice. A sub-sample of volunteers will undergo MRI imaging pre- and post intervention to acquire cerebral blow flow information.


Eligibility criteria: Inclusion Criteria:

* In good general health i.e. no major health condition such as diabetes
* BMI \< 30
* Cholesterol \< 6 and BP \< 150/90
* Not on blood pressure medication or blood thinning medication such as aspirin - No learning difficulty such as dyslexia

Exclusion Criteria:

* Diabetes
* Gastro-intestinal disease
* High BMI
* Cholesterol and BP
* Smoker
* On blood pressure medication or blood thinning medication such as aspirin
* Dyslexic/dyspraxic
* Depression or history of depression

Primary outcomes:
measure: Executive function - Attention
timeFrame: change in attention from baseline and 8 weeks
Secondary outcomes:
measure: Plasma flavanones
timeFrame: change from baseline to 8 weeks
measure: Blood pressure
timeFrame: change from baseline to 8 weeks
Other outcomes:
Locations:
city: Reading
country: United Kingdom
facility: University of Reading
state: Berkshire
Study officials:
affiliation: University of Reading
name: Jeremy PE Spencer, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Reading
name: Laurie T. Butler, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kean RJ, Lamport DJ, Dodd GF, Freeman JE, Williams CM, Ellis JA, Butler LT, Spencer JP. Chronic consumption of flavanone-rich orange juice is associated with cognitive benefits: an 8-wk, randomized, double-blind, placebo-controlled trial in healthy older adults. Am J Clin Nutr. 2015 Mar;101(3):506-14. doi: 10.3945/ajcn.114.088518. Epub 2015 Jan 14.